Lv1
30 积分 2022-07-15 加入
Tafasitamab, lenalidomide, and rituximab in relapsed or refractory follicular lymphoma (inMIND): a global, phase 3, randomised controlled trial
5天前
已完结
Infusion-related reactions to rituximab: frequency, mechanisms and predictors
22天前
已完结
Inebilizumab for Treatment of IgG4-Related Disease
2个月前
已完结
Safety and efficacy of nipocalimab in adults with generalised myasthenia gravis (Vivacity-MG3): a phase 3, randomised, double-blind, placebo-controlled study
4个月前
已完结
A New Era in the Treatment of Myasthenia Gravis: Six New Medications in The Last 6 Years
4个月前
已完结
Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study
5个月前
已完结
Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study
5个月前
已完结
Pembrolizumab with or without chemotherapy in recurrent or metastatic head and neck squamous cell carcinoma: 5-year follow-up from the randomized phase III KEYNOTE-048 study
5个月前
已完结
Lenalidomide in follicular lymphoma
6个月前
已完结
IBCL-378: Epcoritamab Monotherapy Demonstrates Deep and Durable Responses at 3-Year Follow-Up in Patients With Relapsed/Refractory Follicular Lymphoma
6个月前
已完结
皖公网安备34019202002308
